Tech Company Financing Transactions

Inozyme Pharma Funding Round

Inozyme Pharma, based in Boston, raised $67 million from Pivotal bioVenture Partners, Sofinnova Ventures and Cowen Capital Partners.

Transaction Overview

Company Name
Inozyme Pharma
Announced On
4/11/2019
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Investors

Pivotal bioVenture Partners (Lead Investor) (Robert Hopfner)

Sofinnova Ventures (Lead Investor) (Sarah Bhagat)

Cowen Capital Partners

Longitude Capital Management

New Enterprise Associates

Novo Ventures

RA Capital

Rock Springs Capital

Sanofi-Genzyme BioVentures

Proceeds Purpose
The Company will use the proceeds from the Series A2 financing to advance its lead enzyme replacement therapy, INZ-701, into clinical development for severe disorders of calcification associated with deficiencies in the enzyme ENPP1, including Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
280 Summer St. 5th Floor
Boston, MA 02210
USA
Phone
(857) 330-4340
Website
www.inozyme.com
Email Address
[email protected]
Overview
Inozyme Pharma (Nasdaq: INZY) is a biotechnology company developing new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone.
Profile
Inozyme Pharma LinkedIn Company Profile
Social Media
Inozyme Pharma Company Twitter Account
Company News
Inozyme Pharma News
Facebook
Inozyme Pharma on Facebook
YouTube
Inozyme Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Axel Bolte
  Axel Bolte LinkedIn Profile  Axel Bolte Twitter Account  Axel Bolte News  Axel Bolte on Facebook
Chief Operating Officer
Henric Bjarke
  Henric Bjarke LinkedIn Profile  Henric Bjarke Twitter Account  Henric Bjarke News  Henric Bjarke on Facebook
Chief Scientific Officer
David Thompson
  David Thompson LinkedIn Profile  David Thompson Twitter Account  David Thompson News  David Thompson on Facebook
Chief Technical Officer
Steven Jungles
  Steven Jungles LinkedIn Profile  Steven Jungles Twitter Account  Steven Jungles News  Steven Jungles on Facebook
VP - Finance
Stephen Basso
  Stephen Basso LinkedIn Profile  Stephen Basso Twitter Account  Stephen Basso News  Stephen Basso on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/11/2019: Aurora Solar venture capital transaction
Next: 4/12/2019: Mavenlink venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.